Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...

These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to ...

With midyear approaching, the main Wall Street stock indexes are back within a hair's breadth of new records, helped along by ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Ciara Lee reports.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...